FindTrial
Sign In

MTP-PE/MF59

BIOLOGICAL4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsHIV Seronegativity

Phase 1

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
CompletedNCT00001019
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Target: 48Updated: 2012-10-30
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
CompletedNCT00001042
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-03-31Updated: 2021-11-04
A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
CompletedNCT00000972
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 1992-04-30Updated: 2021-11-04
A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)
CompletedNCT00000958
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1995-09-30Target: 8Updated: 2021-11-04